BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a pathological complete response, which was the primary endpoint. We present secondary patient outcomes, including disease-free survival, a specified endpoint by protocol, and data for distant recurrence-free interval, and overall survival, which were not pre...
Background: Bevacizumab is a new humanised monoclonal antibody which targets vascular endothelial gr...
Jinli Wei,* Yulin Luo,* Deyuan Fu Department of Thyroid and Breast Surgery, Northern Jiangsu People...
Purpose Bevacizumab improves progression-free survival but not overall survival in patients with met...
Background: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane...
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in tripl...
SummaryBackgroundThe ARTemis trial was developed to assess the efficacy and safety of adding bevaciz...
Results from previous randomised controlled trials (RCTs) investigating whether the addition of beva...
Background: The addition of bevacizumab to chemotherapy improves progression-free survival in metast...
Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevaci...
Background: Neoadjuvant anthracycline- and taxane-based chemotherapy is frequently administered in b...
Neoadjuvant therapy is administered to breast cancer patients as an induction process before surgery...
$\textbf{Background:}$ The ARTemis trial previously reported that addition of neoadjuvant bevacizuma...
Background: The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab...
Background: The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab ...
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable brea...
Background: Bevacizumab is a new humanised monoclonal antibody which targets vascular endothelial gr...
Jinli Wei,* Yulin Luo,* Deyuan Fu Department of Thyroid and Breast Surgery, Northern Jiangsu People...
Purpose Bevacizumab improves progression-free survival but not overall survival in patients with met...
Background: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane...
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in tripl...
SummaryBackgroundThe ARTemis trial was developed to assess the efficacy and safety of adding bevaciz...
Results from previous randomised controlled trials (RCTs) investigating whether the addition of beva...
Background: The addition of bevacizumab to chemotherapy improves progression-free survival in metast...
Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevaci...
Background: Neoadjuvant anthracycline- and taxane-based chemotherapy is frequently administered in b...
Neoadjuvant therapy is administered to breast cancer patients as an induction process before surgery...
$\textbf{Background:}$ The ARTemis trial previously reported that addition of neoadjuvant bevacizuma...
Background: The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab...
Background: The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab ...
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable brea...
Background: Bevacizumab is a new humanised monoclonal antibody which targets vascular endothelial gr...
Jinli Wei,* Yulin Luo,* Deyuan Fu Department of Thyroid and Breast Surgery, Northern Jiangsu People...
Purpose Bevacizumab improves progression-free survival but not overall survival in patients with met...